M2 PRESSWIRE-May 16, 2017-Cutaneous Squamous Cell Carcinoma Market Insights, Epidemiology and Market Forecasts 2017-2023
(C)1994-2017 M2 COMMUNICATIONS
RDATE:16052017
Dublin – Research and Markets has announced the addition of the “Cutaneous Squamous Cell Carcinoma – Market Insights, Epidemiology and Market Forecast – 2023” drug pipelines to their offering.
The market size for Cutaneous Squamous Cell Carcinoma of 7MM is estimated to grow at a CAGR of 6.1% for the forecast period
Cutaneous Squamous Cell Carcinoma (cSCC)- Market Insights, Epidemiology and Market Forecast – 2023 – 7MM report provides an overview of the disease and global market size of the Cutaneous Squamous Cell Carcinoma for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the Incident cases of Cutaneous Squamous Cell Carcinoma from 2013-2023.
Cutaneous Squamous Cell Carcinoma is a keratinocytic or non-melanoma skin cancer. cSCC is considered the second most common human malignancy after basal cell carcinoma (BCC).Actinic keratosis is the premalignant precursor for cSCC and early treatment might reduce patient morbidity. Unlike almost all basal-cell carcinomas, cutaneous squamous cell carcinomas are associated with a substantial risk of metastasis. The prognosis is favorable and only 2-5% of SCC metastasize.
Key Topics Covered:
– Report Introduction
– Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview at a Glance
– 7 Major Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) (2013-2023)
– Total Market Share Distribution of Cutaneous Squamous Cell Carcinoma for MM
– Total Market Share Distribution of Cutaneous Squamous Cell Carcinoma for MM in
– Introduction
– Signs and Symptoms
– Pathophysiology
– Sub-types of cSCC
– Risk Factors
– Staging of cSCC
– Diagnosis
– Epidemiology and Patient Population
– Total number of Incident cases – MM Countries – (2016 &3)
– Treatment Algorithm
– United States
– NCCN Guidelines
– Europe
– British Association of dermatology (BAD) Guidelines
– French Dermatology Recommendations Association (aRED)
– European Dermatology Forum
– London Cancer Skin Pathway Board
– National Cancer Institute
– Unmet Needs
– Marketed Drugs
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/xvn82g/cutaneous